Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTHROMCOVID: Tinzaparin Dosing in COVID-19
NCT04730856Completed
- Sponsor
- Hospital Universitario Infanta Leonor
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tinzaparin in COVID-19 pneumonia (3 arms), sponsored by Hospital Universitario Infanta Leonor. Primary endpoints: Combined variable including reduction of suspicion of systemic thrombotic symptomatic events, use of mechanical ventilation, and overall survival at 30 days, Reduction of suspicion of systemic thrombotic symptomatic events at 30 days and 2 more. Started Feb 2021; status: completed.
02
Drugs
tinzaparin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04730856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730856.